Appeals court considers future of nationwide access to medication abortion

Appeals Court Examines Louisiana Challenge to Telehealth Abortion Pill Rules

Earthguardiansonline.com – A federal appeals court in New Orleans heard arguments Wednesday in a case that could shape nationwide access to medication abortion, particularly the ability of patients to receive mifepristone through the mail after a telehealth appointment.

Louisiana is challenging federal regulations that permit the drug to be prescribed without an in-person visit and delivered to patients. State officials contend that those rules weaken Louisiana’s abortion restrictions. The dispute is part of a long-running campaign by abortion opponents to limit medication abortion, which now represents about two-thirds of abortions in the United States.

Abortion totals have risen overall since the Supreme Court’s 2022 decision removed the nationwide constitutional protection for abortion. That broader shift has increased attention on medication abortion, interstate access and the federal government’s role in regulating prescription drugs.

A dispute over the FDA’s authority

The three-judge panel of the 5th US Circuit Court of Appeals spent roughly 100 minutes considering whether Louisiana had a valid basis to sue and what power the court would have to alter the Food and Drug Administration’s approach to mifepristone.

The Justice Department urged the court to reject the challenge on procedural grounds. Its lawyers argued that Louisiana had not established the type of direct injury required for a federal lawsuit. At the same time, the department did not embrace the drug’s safety record during the hearing, instead concentrating on whether the case should proceed at all.

Judge Priscilla Richman questioned whether the record showed that the FDA had approved mailing the medication into states where doing so would violate state law. Richman was appointed by President George W. Bush.

“I’m having trouble finding anywhere in the record that the FDA has approved the mailing of this drug into states where it’s unlawful to do that,” Richman told Louisiana Solicitor General Ben Aguiñaga.

Several members of the panel referred to Supreme Court decisions that have limited lawsuits based on indirect or extended chains of alleged harm. Those precedents include an earlier abortion-pill case filed by anti-abortion doctors. In that matter, the Supreme Court concluded that the challengers did not have standing to seek broad restrictions on mifepristone.

Standing remains a central question

Standing is a threshold legal issue. Before a court addresses the merits of a challenge, the party bringing it generally must show a concrete injury that can be addressed by judicial action. Louisiana maintains that the federal rules interfere with its ability to enforce its abortion laws. Federal lawyers argue that the claimed connection is too indirect for the state to proceed.

Justice Department attorney Daniel Winik told the appeals court that the standing issue should end the case. When judges pressed him on Louisiana’s arguments against the FDA’s regulatory decisions, he avoided offering a substantive defense of the agency’s current policy.

Judge Stephen Higginson expressed frustration after Winik said he was not authorized to state whether Louisiana needed to pursue its concerns through the federal regulatory process before filing suit. Higginson, an appointee of President Barack Obama, repeatedly returned to the question of whether courts should override an agency’s medical and regulatory judgments.

The panel also included Judge Dana Douglas, appointed by President Joe Biden. Although the 5th Circuit is widely viewed as conservative, the judges assigned to this stage of the case were seen as having a more moderate-to-left ideological balance than the court overall.

Supreme Court likely to have final say

Whatever the 5th Circuit decides, the dispute is expected to reach the Supreme Court. In May, the high court issued an emergency order preserving the existing telehealth rules while this round of litigation continues. That order limited the immediate options available to the appellate judges and became a frequent topic during Wednesday’s arguments.

Higginson pointed to rulings from courts elsewhere in the country that criticized the FDA for imposing overly restrictive medication-abortion rules. He also cited a 2021 Supreme Court ruling that reversed a lower-court order requiring the FDA to permit telehealth abortion care during the Covid-19 pandemic.

“I guess what I’m saying – and then Chief Justice Roberts writes — it looks like the Supreme Court is being constant with one principle: Let FDA do its work,” Higginson said.

Still, the panel did not dismiss Louisiana’s criticism of the agency’s decisions. Judges asked about the research and information considered by the FDA when it adopted the current rules, as well as the administrative mechanisms available for seeking reconsideration of those regulations.

Political pressure surrounds the case

The litigation has created pressure on the Trump administration from anti-abortion organizations, which have criticized the FDA for not independently moving to end telehealth prescribing of medication abortion. Those groups have also objected to the administration’s opposition to lawsuits seeking judicial restrictions.

The FDA has said it is reviewing mifepristone’s safety profile and has requested that the case be paused while that review is underway. Anti-abortion advocates argue that the agency is delaying action for political reasons. Reproductive-rights organizations, meanwhile, fear that federal officials could restrict access to medication abortion after the midterm elections.

Mifepristone is used with another medication in a two-drug regimen for medication abortion. The legal fight is not solely about one prescription rule: it raises broader questions about state abortion bans, federal drug regulation, telehealth care and the extent to which courts may intervene in agency decisions. The next ruling from the 5th Circuit could clarify those questions, but it is unlikely to settle the national dispute permanently.